Best Life Sciences Companies in Jerusalem, Israel
The 127 best Life Sciences companies in Jerusalem, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Gamida Cell.
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Jerusalem
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Gamida Cell Developer of cell therapies to treat cancer and other serious diseases | $139M | 107 mo ago | 146 | Joseph Wiley CEO and Chairman | WordPressApple iCloud MailMySQL+22 | 211 patents Allogeneic NK and gamma‑delta T cell immunotherapy manufacturing from cord‑derived cells | 1 partnership |
| 2 | Nanox Developer of digital X-ray source | $137M | 70 mo ago | 180 | — | WordPressApple iCloud MailMicrosoft 365+33 | — | 4 launchs · 1 expansion |
| 3 | NovellusDx Developer of technology for precision cancer diagnosis and therapies | $86M | 68 mo ago | 49 | — | — | 46 patents Patient-specific cancer mutation identification, functional validation, and drug response profiling | — |
| 4 | KAHR Developer of immune therapeutics to treat cancer | $58M | 43 mo ago | 32 | Yaron Pereg CEO | — | — | — |
| 5 | BrainQ Developer of AI-powered electromagnetic stimulation technology for stroke disability recovery | $49M | 53 mo ago | 44 | Yaron Segal Founder & CTO | WebflowYouTubeGSAP+16 | 3 patents Non‑invasive electromagnetic neurostimulation for nerve regeneration and repair | — |
| 6 | Brainsway Develoepr of noninvasive neurostimulation treatments for mental health disorders 48Funding top 29%Tech top 35%Patents top 37%Moat top 41% All 11 signals ▾Fundingtop 29% Techtop 35% Patentstop 37% Moattop 41% Innovationtop 43% AItop 45% Globalbottom 49% Talentbottom 49% Growthbottom 47% Newsbottom 24% Marketbottom 23% Funding: Raised $40.5M across 4 rounds · 4 rounds over 12 yrs (0.3/yr) Tech: 59 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 48/100 | $40M | 20 mo ago | 1 | Hadar Levy Chief Executive Officer | WordPressMySQLPHP+34 | 112 patents Non‑invasive transcranial magnetic stimulation hardware and closed‑loop brain‑stimulation systems | — |
| 7 | Illumigyn Developer of colonoscope for cervical cancer detection interventional procedures | $38M | 55 mo ago | 25 | Lior Greenstein Executive Board Member Founder Technology Advisor | — | 38 patents Gynecological optical speculum devices for in‑vivo imaging and targeted tissue removal | — |
| 8 | Omnix Medical Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections 42Product top 25%Funding top 30%Tech top 33%Moat top 38% All 8 signals ▾Producttop 25% Fundingtop 30% Techtop 33% Moattop 38% Patentstop 44% Innovationtop 47% Globalbottom 43% Marketbottom 30% Product: 4 distinct product lines · Company stage: Series C Funding: Raised $24.3M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $24M | 8 mo ago | 17 | — | WordPressMySQLPHP+27 | 30 patents Antimicrobial peptide therapeutics targeting infectious diseases and related medical applications. | — |
| 9 | Oramed Developer of oral reformulations to treat various health conditions | $23M | 74 mo ago | 17 | — | WordPressMySQLPHP+22 | 102 patents Oral delivery of peptide/protein therapeutics for diabetes and liver disease | — |
| 10 | Enlivex Pharmaceuticals Developer of autologous and allogeneic cell immunotherapy therapy treatments 55News top 14%Growth top 22%Funding top 32%Moat top 39% All 8 signals ▾Newstop 14% Growthtop 22% Fundingtop 32% Moattop 39% Marketbottom 48% Techbottom 42% Talentbottom 41% Globalbottom 37% News: 15 BI events in 12 mo (of 30 tracked, 9 types) · +650% YoY Growth: Web rank 50,000,000 → 10,000,000 YoY · 2 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $15M | 6 mo ago | 77 | Oren Hershkovitz CEO | WordPressMySQLPHP+24 | — | — |
| 11 | RealSense Developer of urine flow monitoring device for real-time renal diagnostics | $14M | 54 mo ago | 18 | Avi Kleiman CEO | — | 2 patents Computer vision-based perception and safety monitoring for autonomous vehicles | — |
| 12 | Regencure Biocompatible polymeric membrane implants for bone reconstruction | $12M | 156 mo ago | — | Moshe Tzabari Founder & CEO | — | — | — |
| 13 | Oridion Provider of device for assessment of patient’s breathing quality in clinics | $10M | 336 mo ago | 66 | Yacov Bubis Co-Founder & COO | — | — | — |
| 14 | Vidac Pharma HK2-VDAC protein interaction disruptors for oncologic and oncodermatologic diseases. 21Product top 36%Growth top 45%Patents top 47%Moat top 47% All 9 signals ▾Producttop 36% Growthtop 45% Patentstop 47% Moattop 47% Innovationbottom 48% Fundingbottom 45% Techbottom 36% Globalbottom 35% Marketbottom 23% Product: 8 distinct product lines · Company stage: Series A Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $10M | 19 mo ago | 9 | — | JoomlaPHPBootstrap+9 | 44 patents Patents concentrated in health & consumer products | — |
| 15 | Pepticom Developer of AI-based technology for the discovery of peptide drug candidates 35Moat top 31%Growth top 35%Product top 36%AI top 45% All 10 signals ▾Moattop 31% Growthtop 35% Producttop 36% AItop 45% Techbottom 46% Patentsbottom 45% Fundingbottom 40% Globalbottom 40% Innovationbottom 37% Marketbottom 29% Moat: Editorial + unicorn rating 7/10 · IP moat: 15 patents Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $8M | 17 mo ago | 18 | — | WordPressMySQLPHP+20 | 15 patents Patents concentrated in health & consumer products | — |
| 16 | Senseera Provider of liquid biopsy blood tests for cancer diagnosis 35Talent top 28%Funding top 46%Market bottom 37%Global bottom 36% All 4 signals ▾Talenttop 28% Fundingtop 46% Marketbottom 37% Globalbottom 36% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $7.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $7M | 17 mo ago | — | Nir Friedman Co-Founder | — | — | — |
| 17 | Izun Pharma Biopharmaceutical company developing powerful non-steroidal topical oral anti-inflammatory therapies | $5M | 139 mo ago | 12 | — | — | — | — |
| 18 | IntecPharma Drug delivery technology to improve pharmacokinetics and pharmacodynamics of drugs for Parkinson's, insomnia… | $5M | 78 mo ago | 14 | — | — | — | — |
| 19 | VOTIS AI-based device and platform for diagnosing diabetic patient feet | $5M | 38 mo ago | 16 | — | — | — | — |
| 20 | ProtAb Developing immunotherapeutic mAb for autoimmune inflammatory diseases | $4M | 194 mo ago | — | Shira Yair Ex-CEO | — | 25 patents Humanized therapeutic antibodies targeting HSP65 peptide-6 and CAP1 for immunomodulation | — |
| 21 | MAOLAC Developing antibodies and nutrients enriched preventive nutritional products. | $3M | 47 mo ago | 19 | Eli Lerner Co-Founder | WordPressMySQLPHP+23 | 9 patents Immunomodulatory compositions that enhance immune system function (vaccines/adjuvants). | — |
| 22 | HIL Medical Developer of proton-beam radiotherapy device to treat solid tumors | $3M | 37 mo ago | — | Arie Zigler Co-Founder | Cart FunctionalityRequireJSReact+10 | 42 patents Advanced ion/charged-particle therapy systems for precise cancer radiation delivery | — |
| 23 | Eventus Diagnostics Immune system-based blood tests for the detection of breast cancer | $3M | 146 mo ago | — | Marvin Rosenberg Co-Founder & President | — | 5 patents Immunoassay-based detection of cancer biomarkers | — |
| 24 | Opticul Diagnostics In-vitro diagnostics device for point-of-care microorganism identification | $2M | 141 mo ago | 11 | Israel Gannot CEO | — | 25 patents Rapid spectroscopic detection and identification of microorganisms in clinical samples | — |
| 25 | Tiltan Pharma Develops therapeutics for treatment of metastatic pancreatic cancer using combinatorial drug therapy… | $2M | 148 mo ago | — | Yigal Stav CEO & Co-Founder | — | 29 patents Oncologic combination drug regimens integrating H2 blockers, anti-inflammatories, and cytotoxics | — |
| 26 | Immunovative Therapies Developing personalized vaccines and activated T cells for the treatment of cancer and infectious diseases. | $2M | 221 mo ago | 18 | — | — | 287 patents Cell-based immunotherapies modulating Th1/Treg cytokines for infectious disease treatment | — |
| 27 | Hervana Developing probiotic-based therapies as contraceptives | $1M | 161 mo ago | 3 | Rachel Teitelbaum Founder & CEO | — | 20 patents Engineered probiotic Lactobacillus delivering anti‑sperm antibodies for female contraception | — |
| 28 | BioMarCare Developer of biomarkers for cardiovascular disease risk assessment and management | $1M | 170 mo ago | 5 | Dana Cohen Founder & CEO | — | — | — |
| 29 | ISK Human secreted peptides for malignant and autoimmune diseases | $800K | 133 mo ago | — | — | — | — | — |
| 30 | LipoMedix Provider of Israeli clinical-stage biotech developing PEG-ylated liposomal Mitomycin drugs for cancer | $639K | 78 mo ago | — | Alberto Gabizon Founder & CEO | — | — | — |
| 31 | NIMD Noninvasive microwave heating technology for cancer treatment | $600K | 124 mo ago | — | Anan Copty Co-Founder & CEO | — | 3 patents Microwave-driven hyperthermia ablation and nanoparticle‑enhanced cancer detection imaging | — |
| 32 | AmnioTix Medical Spectroscopy-based medical device for the assessment of fetal well-being | $550K | 192 mo ago | — | Ehud Nachtomy CEO | — | — | — |
| 33 | Marx Biotechnology Developer of molecular diagnostic kit for the early detection of Graft Versus Host Disease | $500K | 173 mo ago | 3 | Stephen Marx Founder & CEO | — | — | — |
| 34 | Immunyx Developer of neutrophil therapies for multiple diseases | $269K | 48 mo ago | 7 | Zvi Fridlender Co-Founder | — | — | — |
| 35 | RespiDx Developer of respirometer for the early diagnosis of pneumonia | $150K | 122 mo ago | — | Yossi Aldar Founder & CEO | — | 5 patents Oral cavity-based vital sign sensing devices and methods | — |
Top 12 Life Sciences companies in Jerusalem
#1
Series C · Jerusalem, Jerusalem District · founded 2015 · 17 employees$24.3Mraised▾
Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections. The lead candidate OMN6 targets gram-negative bacteria. Other candidates include OMN-XF for multi-drug resistance fungi and OMN-XGP for gram-positive bacteria. The technology is based on natural antimicrobial peptides which are genetically engineered for stability and for proteolytic degradation pruning.
- Oct 2025Series C$25M
- Oct 2023Grant (prize money)$52.9K
- Aug 2021Grant (prize money)—
- Jul 2021Grant (prize money)$2.8M
#2
Public · Jerusalem, Jerusalem District · founded 2005 · 77 employees$15Mraised▾
Enlivex Pharmaceuticals, a cell immunotherapy company, is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions. Its clinical development programs focus on GvHD (graft versus host disease), CAR-T, and autoimmune diseases; Allocetra™, has been developed for the prevention of acute GvHD (Phase 2/3), particularly severe, or high-grade, acute GvHD (orphan drug designation); Allocetra consists of retrieving a blood sample from the patient or a matched donor, treating it at the cellular level to generate an early apoptotic cell population undergoing apoptosis and injecting it into the patient; Enlivex is also examining the potential for collaborating with leading CAR-T companies in clinical studies to evaluate the efficacy and side effect profile of CAR-T treatments for a variety of cancer-related clinical indications, such as blood cancers and solid tumors.
- Nov 2025Post IPO$212M
- Apr 2019Post IPO$8.4M
- Sep 2017Post IPO$8M
- May 2014Series A$7M
#3
Public · Jerusalem, Jerusalem District · founded 2003 · 1 employees$40.5Mraised▾
Develoepr of noninvasive neurostimulation treatments for mental health disorders. The company uses proprietary technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment. It is used to treat depressive episodes in patients suffering from Major Depressive Disorder.
- Sep 2024Post IPO$20M
- Dec 2017Post IPO$8.5M
- Jan 2016Grant (prize money)$163.7K
- Mar 2014Post IPO$11.8M
#4
Series A · Jerusalem, Jerusalem District · founded 2011 · 18 employees$7.6Mraised▾
Developer of AI-based technology for the discovery of peptide drug candidates. The platform's technology is an algorithm that assists in protein-protein interface and peptide-protein interface enabling the design of binding peptides, agonists, and antagonists that are intended to block protein-protein interactions. It analyzes the target surface surrounding the desired binding area and then performs a design process to provide a peptide library with optimal binding affinity.
- Jan 2025Series A$6.6M
- Mar 2021Series A$2.6M
- Oct 2019Series A$5M
- Aug 2013Seed—
#5
Seed · Jerusalem, Jerusalem District · founded 2020$7.1Mraised▾
Provider of liquid biopsy blood tests for cancer diagnosis. The cfChIP-seq technology can detect cell-free chromatin tissue which can be used to identify patient-specific gene expression for the detection of diseases and treatment response. The company uses molecular biology, next-generation sequencing, and computational analysis to extract epigenetic information.
- Jan 2025Seed$7.1M
#6
Series A · Jerusalem, Jerusalem District · founded 2011 · 9 employees$9.6Mraised▾
Vidac Pharma is focussed on developing medicines for a range of oncologic and oncodermatologic diseases. Its technology is based on modifying the HK2 (hexokinase enzyme)-VDAC (voltage-dependent anion channel) system which overexpresses in many cancer types. It is developing small molecule drugs which disrupt the protein interactions and can modulate this target for the selective apoptosis of cancer cells. Its lead product VDA-1102, a formulated topical ointment is being developed for actinic keratosis (phase 1 completed), Cutaneous Squamous Cell Carcinoma (phase 1) and Cutaneous Skin Lymphoma & solid tumors (pre-clinical). Besides, it is also developing VDA-1214, a systemic drug for treatment of solid tumors (pre-clinical).
- Nov 2024Series A$644.9K
- Jun 2016Series A$9M
#7
Series D · Jerusalem, Jerusalem District · founded 2005 · 32 employees$58.5Mraised▾
Developer of immune therapeutics to treat cancer. The company's product candidates include DSP107 SIRPα-41BBL, DSP105 PD1-41BBL, and TSPs TIGIT/LILRB/SIGLEC used for the treatment of solid tumour. The company has developed its proprietary MIRP (Multifunctional Immune Recruitment Protein) technology for the discovery of immuno-recruitment drugs. It is used to target the immune checkpoints for unmasking cancer camouflage mechanisms.
- Nov 2022Series D—
- May 2021Series C$46.5M
- Jan 2019Grant (prize money)$151.5K
- Dec 2015Series B$12M
#8
Public · Jerusalem, Jerusalem District · founded 2004 · 180 employees$137Mraised▾
Nanox is a developer of the novel digital X-ray source. The digital system developed by the company is called Nanox.ARC which transmits to its cloud platform. The cloud platform is available to the health care provider for real-time diagnostics.
- Jul 2020Series B$59M
- Jun 2020Series B$20M
- Jan 2020Series B$26M
- Apr 2016Series A$1.4M
#9
Series B · Jerusalem, Jerusalem District · founded 2011 · 44 employees$48.8Mraised▾
Developer of AI-powered electromagnetic stimulation technology for stroke disability recovery. The investigational therapy uses tailored, low-intensity, low-frequency electromagnetic stimulation to enhance the brain’s recovery process. The device is designed for safe use in clinical and home settings. The therapy aims to help patients regain independence and improve neurological conditions.
- Dec 2021Grant (prize money)$56.6K
- Aug 2021Series B$40M
- Jan 2020Grant (prize money)$2.5M
- Nov 2018Grant (prize money)$56.9K
#10
Series C · Jerusalem, Jerusalem District · founded 2011 · 49 employees$85.5Mraised▾
Developer of technology for precision cancer diagnosis and therapies. The company's technology allows monitoring the outcomes of known and unknown DNA mutations, the function & clinical significance of each mutation, and the activity of the drug(s) on a specific tumor.
- Sep 2020Series C$57M
- Apr 2018Series B$6M
- Jun 2016Series B$12.5M
- Dec 2015Series A$10M
#11
Public · Jerusalem, Jerusalem District · founded 1998 · 146 employees$139.1Mraised▾
Developer of cell therapies to treat cancer and other serious diseases. The company is pioneering a proprietary NAM platform for allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapies for solid tumors. The lead product of the company is omidubicel for the treatment of hematological malignancies.
#12
Series B · Jerusalem, Jerusalem District · founded 2014 · 25 employees$38Mraised▾
Developer of colonoscope for cervical cancer detection interventional procedures. The product Gynescope is a patented imaging colposcope coupled with multispectral illumination options that can be used for the early detection of cervical cancer. It also claims that the Gynescope is the only colposcope that allows the imaging with simultaneous complex interventional procedures to support the best clinical outcomes.
- Nov 2021Series B$33M
- Nov 2016Series A$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Jerusalem researches in biotechnology
Hebrew University leads Jerusalem's biotech research, focusing on plant-microbe interactions and biosensing techniques, with a cautiously optimistic tone (mean stance 0.39) balancing breakthroughs against concerns.
- Hebrew University of Jerusalem29
- Jerusalem University College1
- Azrieli College of Engineering Jerusalem1
- Jerusalem Institute for Israel Studies1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.